A case of influenza associated fulminant myocarditis successfully treated with intravenous peramivir

Seung Hee Baik, Han Saem Jeong, Sun Jin Kim, Young Kyung Yoon, Jang Wook Sohn, Ja Kim Min

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We report the case of a patient with fulminant myocarditis caused by influenza A virus, who presented with acute-onset heart failure and cardiogenic shock and was treated successfully with single dose of intravenous peramivir and with pharmacologic hemodynamic support. A 45-year-old Korean woman presented to our emergency department (ED) with shortness of breath and an episode of seizure that developed abruptly 5 hours before she arrived in the ED. She had a history of recurrent epileptic seizure 25 years ago, but denied other specific medical illnesses. In the ED, she was hypoxemic (arterial partial pressure of oxygen, 59.8 mmHg on room air) and chest radiography revealed bilateral alveolar infiltrates. A rapid antigen test for influenza A virus was positive, and she was administered a single dose of peramivir (300 mg) intravenously. Five hours later, the patient's dyspnea had worsened and she was hypotensive (blood pressure, 86/53 mmHg), requiring norepinephrine infusion. Further evaluation disclosed an increased cardiac troponin I level of 1.36 ng/mL and a depressed left ventricular ejection fraction of 30%. Under the diagnosis of influenza A-associated myocarditis and cardiogenic shock, she was managed with continuous critical care in the intensive care unit. On day 3, the patient's dyspnea began to resolve and her ventricular function returned to normal. Real-time polymerase chain reaction assays for influenza viruses in serial nasopharyngeal aspirates were positive for influenza A (hH3N2) with a threshold cycle value of 27.39 on day 2, but these became negative by day 4. The patient recovered and was discharged on day 9 after admission. In conclusion, this case indicates that intravenous peramivir might be an effective antiviral agent for the treatment of severe influenza A virus infection.

Original languageEnglish
Pages (from-to)272-277
Number of pages6
JournalInfection and Chemotherapy
Volume47
Issue number4
DOIs
Publication statusPublished - 2015

Fingerprint

Myocarditis
Human Influenza
Influenza A virus
Dyspnea
Hospital Emergency Service
Cardiogenic Shock
Pneumoradiography
Troponin I
Ventricular Function
Partial Pressure
Virus Diseases
Critical Care
Orthomyxoviridae
Stroke Volume
Antiviral Agents
Intensive Care Units
Real-Time Polymerase Chain Reaction
Epilepsy
Norepinephrine
Arterial Pressure

Keywords

  • Influenza A
  • Myocarditis
  • Neuraminidase inhibitors
  • Peramivir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

A case of influenza associated fulminant myocarditis successfully treated with intravenous peramivir. / Baik, Seung Hee; Jeong, Han Saem; Kim, Sun Jin; Yoon, Young Kyung; Sohn, Jang Wook; Min, Ja Kim.

In: Infection and Chemotherapy, Vol. 47, No. 4, 2015, p. 272-277.

Research output: Contribution to journalArticle

@article{6edffe1c358f4b778d0dbe267d9d79c4,
title = "A case of influenza associated fulminant myocarditis successfully treated with intravenous peramivir",
abstract = "We report the case of a patient with fulminant myocarditis caused by influenza A virus, who presented with acute-onset heart failure and cardiogenic shock and was treated successfully with single dose of intravenous peramivir and with pharmacologic hemodynamic support. A 45-year-old Korean woman presented to our emergency department (ED) with shortness of breath and an episode of seizure that developed abruptly 5 hours before she arrived in the ED. She had a history of recurrent epileptic seizure 25 years ago, but denied other specific medical illnesses. In the ED, she was hypoxemic (arterial partial pressure of oxygen, 59.8 mmHg on room air) and chest radiography revealed bilateral alveolar infiltrates. A rapid antigen test for influenza A virus was positive, and she was administered a single dose of peramivir (300 mg) intravenously. Five hours later, the patient's dyspnea had worsened and she was hypotensive (blood pressure, 86/53 mmHg), requiring norepinephrine infusion. Further evaluation disclosed an increased cardiac troponin I level of 1.36 ng/mL and a depressed left ventricular ejection fraction of 30{\%}. Under the diagnosis of influenza A-associated myocarditis and cardiogenic shock, she was managed with continuous critical care in the intensive care unit. On day 3, the patient's dyspnea began to resolve and her ventricular function returned to normal. Real-time polymerase chain reaction assays for influenza viruses in serial nasopharyngeal aspirates were positive for influenza A (hH3N2) with a threshold cycle value of 27.39 on day 2, but these became negative by day 4. The patient recovered and was discharged on day 9 after admission. In conclusion, this case indicates that intravenous peramivir might be an effective antiviral agent for the treatment of severe influenza A virus infection.",
keywords = "Influenza A, Myocarditis, Neuraminidase inhibitors, Peramivir",
author = "Baik, {Seung Hee} and Jeong, {Han Saem} and Kim, {Sun Jin} and Yoon, {Young Kyung} and Sohn, {Jang Wook} and Min, {Ja Kim}",
year = "2015",
doi = "10.3947/ic.2015.47.4.272",
language = "English",
volume = "47",
pages = "272--277",
journal = "Infection and Chemotherapy",
issn = "2093-2340",
publisher = "Taehan Kamyom Hakhoe, Taehan Hwahak Yopop Hakhoe",
number = "4",

}

TY - JOUR

T1 - A case of influenza associated fulminant myocarditis successfully treated with intravenous peramivir

AU - Baik, Seung Hee

AU - Jeong, Han Saem

AU - Kim, Sun Jin

AU - Yoon, Young Kyung

AU - Sohn, Jang Wook

AU - Min, Ja Kim

PY - 2015

Y1 - 2015

N2 - We report the case of a patient with fulminant myocarditis caused by influenza A virus, who presented with acute-onset heart failure and cardiogenic shock and was treated successfully with single dose of intravenous peramivir and with pharmacologic hemodynamic support. A 45-year-old Korean woman presented to our emergency department (ED) with shortness of breath and an episode of seizure that developed abruptly 5 hours before she arrived in the ED. She had a history of recurrent epileptic seizure 25 years ago, but denied other specific medical illnesses. In the ED, she was hypoxemic (arterial partial pressure of oxygen, 59.8 mmHg on room air) and chest radiography revealed bilateral alveolar infiltrates. A rapid antigen test for influenza A virus was positive, and she was administered a single dose of peramivir (300 mg) intravenously. Five hours later, the patient's dyspnea had worsened and she was hypotensive (blood pressure, 86/53 mmHg), requiring norepinephrine infusion. Further evaluation disclosed an increased cardiac troponin I level of 1.36 ng/mL and a depressed left ventricular ejection fraction of 30%. Under the diagnosis of influenza A-associated myocarditis and cardiogenic shock, she was managed with continuous critical care in the intensive care unit. On day 3, the patient's dyspnea began to resolve and her ventricular function returned to normal. Real-time polymerase chain reaction assays for influenza viruses in serial nasopharyngeal aspirates were positive for influenza A (hH3N2) with a threshold cycle value of 27.39 on day 2, but these became negative by day 4. The patient recovered and was discharged on day 9 after admission. In conclusion, this case indicates that intravenous peramivir might be an effective antiviral agent for the treatment of severe influenza A virus infection.

AB - We report the case of a patient with fulminant myocarditis caused by influenza A virus, who presented with acute-onset heart failure and cardiogenic shock and was treated successfully with single dose of intravenous peramivir and with pharmacologic hemodynamic support. A 45-year-old Korean woman presented to our emergency department (ED) with shortness of breath and an episode of seizure that developed abruptly 5 hours before she arrived in the ED. She had a history of recurrent epileptic seizure 25 years ago, but denied other specific medical illnesses. In the ED, she was hypoxemic (arterial partial pressure of oxygen, 59.8 mmHg on room air) and chest radiography revealed bilateral alveolar infiltrates. A rapid antigen test for influenza A virus was positive, and she was administered a single dose of peramivir (300 mg) intravenously. Five hours later, the patient's dyspnea had worsened and she was hypotensive (blood pressure, 86/53 mmHg), requiring norepinephrine infusion. Further evaluation disclosed an increased cardiac troponin I level of 1.36 ng/mL and a depressed left ventricular ejection fraction of 30%. Under the diagnosis of influenza A-associated myocarditis and cardiogenic shock, she was managed with continuous critical care in the intensive care unit. On day 3, the patient's dyspnea began to resolve and her ventricular function returned to normal. Real-time polymerase chain reaction assays for influenza viruses in serial nasopharyngeal aspirates were positive for influenza A (hH3N2) with a threshold cycle value of 27.39 on day 2, but these became negative by day 4. The patient recovered and was discharged on day 9 after admission. In conclusion, this case indicates that intravenous peramivir might be an effective antiviral agent for the treatment of severe influenza A virus infection.

KW - Influenza A

KW - Myocarditis

KW - Neuraminidase inhibitors

KW - Peramivir

UR - http://www.scopus.com/inward/record.url?scp=84957652181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957652181&partnerID=8YFLogxK

U2 - 10.3947/ic.2015.47.4.272

DO - 10.3947/ic.2015.47.4.272

M3 - Article

AN - SCOPUS:84957652181

VL - 47

SP - 272

EP - 277

JO - Infection and Chemotherapy

JF - Infection and Chemotherapy

SN - 2093-2340

IS - 4

ER -